AMGN

#82
Amgen Inc. - Common Stock
335.5 8 USD
-0.27%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
334.47
335.65
Yıllık Aralık
267.83
391.29
Günlük Değişim
-0.27%
Aylık Değişim
-1.52%
6 Aylık Değişim
-2.23%
Yıllık Değişim
+18.43%
Önceki Kapanış
336.4 8
Open
334.9 2
Düşük
334.4 7
High
335.6 5
Hacim
777
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler Temettüler
Çeyreklik Yıllık
  • Market Capitalization 181.12 B
  • Employee 32 K
  • Founded 1980
  • CEO Robert A. Bradway
  • Website www.amgen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BBS2Y0
  • Industry İlaç Üreticileri - Genel
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
23
Fiyat/satışlar oranı
4.83
Hisse başına temettü
9.66
Temettü getirisi %
2.95

Amgen Inc. - Common Stock

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

Haberler